Using a System Pharmacology Method to Search for the Potential Targets and Pathways of Yinqiaosan against COVID-19

Li-Hua Cao1, Xing-Yuan Jia2, Hong-Juan He1

  • 1Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China.

Insights

Traditional Chinese Medicine's Yinqiaosan (YQS) shows promise for treating COVID-19 pneumonia. System pharmacology identified active compounds and key pathways, revealing anti-inflammatory and antioxidative mechanisms for effective therapeutic intervention.

Area of Science:

  • Pharmacology and Traditional Chinese Medicine (TCM)

Background:

  • Coronavirus disease 2019 (COVID-19) rapidly spread globally, causing severe respiratory illnesses like pneumonia.
  • Traditional Chinese Medicine (TCM) interventions, including Yinqiaosan (YQS), have been utilized for COVID-19 pneumonia with reported efficacy.
  • A comprehensive understanding of YQS's active compounds and therapeutic mechanisms against COVID-19 pneumonia is lacking.

Purpose of the Study:

  • To investigate the active compounds and therapeutic mechanisms of Yinqiaosan (YQS) in treating COVID-19 pneumonia using system pharmacology.

Main Methods:

  • Employed a system pharmacology approach, including drug-likeness assessment, oral bioavailability forecasting, virtual docking, and network analysis.
  • Identified active compounds, potential targets, and key molecular pathways associated with YQS treatment for COVID-19 pneumonia.

Main Results:

  • Identified 117 active compounds in YQS and 77 potential targets relevant to COVID-19 pneumonia.
  • YQS may treat COVID-19 pneumonia and its complications (atherosclerosis, nephropathy) via pathways including Kaposi sarcoma-associated herpesvirus infection and AGE-RAGE signaling.
  • Key molecular targets identified include TNF, GAPDH, MAPK3, MAPK1, EGFR, CASP3, MAPK8, mTOR, IL-2, and MAPK14; notable compounds possess anti-inflammatory and antioxidative properties.

Conclusions:

  • Systematic network pharmacology effectively predicted the active compounds, targets, and pathways of YQS for COVID-19 treatment.
  • The study provides a comprehensive clarification of YQS's mechanism of action in managing COVID-19 pneumonia and associated conditions.